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ABSTRACT 
Our knowledge of the transcriptome has become much more complex since the days of 
the central dogma of molecular biology.  We now know that splicing takes place to 
create potentially thousands of isoforms from a single gene, and we know that RNA 
does not always faithfully recapitulate DNA if RNA editing occurs.  Collectively, these 
observations show that the transcriptome is amazingly rich with intricate regulatory 
mechanisms for overall gene expression, splicing, and RNA editing.   
 
Genetic variability can play a role in controlling gene expression, which can be 
identified by examining expression quantitative trait loci (eQTLs).  eQTLs are genomic 
regions where genetic variants, including single nucleotide polymorphisms (SNPs) 
show a statistical association with expression of mRNA transcripts. In humans, many 
SNPs are also associated with disease, and have been identified using genome wide 
association studies (GWAS) but the biological effects of those SNPs are usually not 
known.  If SNPs found in GWAS are also found in eQTLs, then one could hypothesize 
that expression levels may contribute to disease risk.  Performing eQTL analysis with 
GWAS SNPs in both blood and brain, specifically the frontal cortex and the 
cerebellum, we found both shared and tissue unique eQTLS. The identification of 
tissue-unique eQTLs supports the argument that choice of tissue type is important in 
eQTL studies (Paper I).   
 
Aging is a complex process with the mechanisms underlying aging still being poorly 
defined.  There is evidence that the transcriptome changes with age, and hence we used 
the brain dataset from our first paper as a discovery set, with an additional replication 
dataset, to investigate any aging-gene expression associations.  We found evidence that 
many genes were associated with aging. We further found that there were more 
statically significant expression changes in the frontal cortex versus the cerebellum, 
indicating that brain regions may age at different rates. As the brain is a heterogeneous 
tissue including both neurons and non-neuronal cells, we used LCM to capture Purkinje 
cells as a representative neuronal type and repeated the age analysis.  Looking at the 
discovery, replication and Purkinje cell datasets we found five genes with strong, 
replicated evidence of age-expression associations (Paper II).  
 
Being able to capture and quantify the depth of the transcriptome has been a lengthy 
process starting with methods that could only measure a single gene to genome-wide 
techniques such as microarray.  A recently developed technology, RNA-Seq, shows 
promise in its ability to capture expression, splicing, and editing and with its broad 
dynamic range quantification is accurate and reliable.  RNA-Seq is, however, data 
intensive and a great deal of computational expertise is required to fully utilize the 
strengths of this method.  We aimed to create a small, well-controlled, experiment in 
order to test the performance of this relatively new technology in the brain. We chose 
embryonic versus adult cerebral cortex, as mice are genetically homogenous and there 
are many known differences in gene expression related to brain development that we 
could use as benchmarks for analysis testing. We found a large number of differences 
in total gene expression between embryonic and adult brain. Rigorous technical and 
biological validation illustrated the accuracy and dynamic range of RNA-Seq.  We 
were also able to interrogate differences in exon usage in the same dataset.  Finally we 
were able to identify and quantify both well-known and novel A-to-I edit sites.  Overall 
this project helped us develop the tools needed to build usable pipelines for RNA-Seq 
data processing (Paper III). 
 
Our studies in the developing brain (Paper III) illustrated that RNA-Seq was a useful 
unbiased method for investigating RNA editing. To extend this further, we utilized a 
genetically modified mouse model to study the transcriptomic role of the RNA editing 
enzyme ADAR2.  We found that ADAR2 was important for editing of the coding 
region of mRNA as a large proportion of RNA editing sites in coding regions had a 
statistically significant decrease in editing percentages in Adar2-/- Gria2R/R mice versus 
controls.  However, despite indications in the literature that ADAR2 may also be 
involved in splicing and expression regulatory machinery we found no changes in gene 
expression or exon utilization in Adar2-/- Gria2R/R mice as compared to their littermate 
controls (Paper IV). 
 
In our final study, based on the methods developed in Papers III and IV, we revisited 
the idea of age related gene expression associations from Paper II.  We used a subset of 
human frontal cortices for RNA sequencing.  Interestingly we found more gene 
expression changes with aging compared to the previous data using microarrays in 
Paper II. When the significant gene lists were analysed for gene ontology enrichment, 
we found that there was a large number of downregulated genes involved in synaptic 
function while those that were upregulated had enrichment in immune function.   This 
dataset illustrates that the aging brain may be predisposed to the processes found in 
neurodegenerative diseases (Paper V).    
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1 INTRODUCTION 
The “central dogma” of molecular biology states that biological information is 
transferred from nucleic acids to proteins as DNA is transcribed into RNA and RNA is 
translated to protein, wherein a single gene made a single protein1. Although DNA 
holds the genetic information to code for an entire multicellular organism, the select 
creation of a subset of RNA species is needed to specify identity in any given cell or 
tissue at any given time. In recent years, we have come to realize that the transcriptome 
is much more complex than the central dogma might imply. Messenger RNA 
molecules are heavily regulated through methods such as RNA splicing, where single 
exons are included or excluded from the mRNA. RNA is also editing by several 
enzymes, leading to differences in sequence from the encoded genome. These 
processes lead to diversification in the encoded proteins. Thus, the transcriptome is 
central to the dynamic transfer of information from DNA to protein.  
 
1.1 MEASURING RNA 
As mRNA is the key intermediate between DNA and protein, it is critical to be able to 
describe the mRNA content in a cell or tissue  qualitatively and quantitatively.  
Historically, many methods have been developed to look at RNA, which will be 
outlined briefly here. 
 
In northern blotting, RNA samples are separated based on size using electrophoresis, 
then transferred via capillary to a membrane that can be blotted using a labeled probe 
complementary to the gene of interest 2,3. As alternate splicing can lead to differences in 
sizes of the RNA, Northern blots can be used to estimate splicing events in some cases. 
Furthermore, Northern blots can be used for quantification of major species.   
 
Accurate quantification of mRNA can also be achieved using quantitative reverse 
transcription polymerase chain reaction (qRT-PCR).   In this method, the first step is to 
reverse transcribe RNA into cDNA.  The cDNA is then amplified using polymerase 
chain reaction with quantification occurring in real time after each cycle.   Detection 
can be done in two ways, using either a non-specific fluorescent reporter such as SYBR 
green or a sequence specific probe such as those found in TaqMan assays. SYBR green 
intercalates with double stranded DNA and as amplification using gene specific primers 
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proceeds, more DNA product is made and fluorescence increases.  TaqMan uses a 
sequence specific probe that contains a fluorophore at its 5’ end and a 3’ quencher, 
which anneals with its complementary DNA region.  As the Taq polymerase 
synthesizes a new copy of the DNA, it degrades the probe through its exonuclease 
activity.  This degradation releases the fluorophore from the quencher, allowing for 
detection.  Both SYBR Green and Taqman assays can be highly accurate with a large 
dynamic range when probes are designed correctly and reference genes are chosen 
appropriately4–8.    
 
Another method, in situ hybridization, uses labeled probes to show the localization of 
individual RNA species within tissues9.  In this approach, sections of tissues are 
incubated with probes of interest therefore allowing for identification of the cells in 
which a given sequence is expressed. This technology has been particularly useful in 
complex tissues such as the brain that contain many cell types and is amenable to large-
scale examination of many genes such as in the Allen Brain Atlas project 
(http://mouse.brain-map.org/).  Furthermore, quantification of in situ signals can be 
achieved by counting silver grains after development of radiolabeled sections with 
photographic emulsion10 or with fluorescent probes11. 
 
All of these methods are generally limited to quantifying a single gene or a small 
handful of genes per experiment and are therefore most effectively applied when there 
is a prior knowledge of which genes to investigate.  However, unbiased genome-wide 
approaches would be useful when trying to find new molecular events associated with a 
given biological events.  Microarray chips contain tens to hundreds of thousands of 
probes providing an ability to assay multiple genes in a single experiment.  Generally, 
the first step in this method is to use reverse transcriptase to convert RNA to cDNA and 
then tag the cDNA with biotin.  Biotinylated cDNA is then hybridized to the 
microarray with cDNA binding to probes that represent the complementary sequences 
and are attached to a support (usually a glass slide).  Next, a series of washes is applied 
to remove unbound cDNA then a fluorescent dye containing streptavidin is added to 
bind to the biotinylated cDNA.  The overall fluorescence at each prove is quantified 
using an array scanner giving relative expression levels of each gene interrogated by 
the array12–14.    
 
There are several known limitations in microarrays, including problems with probe 
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design15,16, a compressed range of sensitivity17,  and statistical concerns18 due to the 
large number of probes measured. For example, non-specific hybridization to 
microarray probes leads to a limited dynamic range19,20.  Because of these limitations, 
validation is generally required for any proposed differences in gene expression 
between groups, with qRT-PCR being the favoured method.  Interestingly there is little 
in the literature that deals with which method is “correct” when these two techniques 
are in not in agreement, either by the differences magnitude of expression differences 
or even in the direction of effect reported.  Etienne at al found that correlation between 
RT-PCR and microarray was highest with moderately expressed genes21, and another 
study found that there was less  correlation between the two methods for down-
regulated genes versus those that were up-regulated22.   Both studies indicate that 
microarray is weak at accurately measuring genes that are expressed at low levels.  
Because of these problems with the accuracy of microarray approaches, other methods 
of quantifying gene expression on a genome-wide level are worth exploring.   
 
1.2 RNA SEQUENCING  
 
Figure 1.  This figure was adapted from van der Brug et al. and Mardis et al. to 
illustrate the steps in library preparation and sequencing for the RNA-Seq 
method23,24. 
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Interrogating the complexity of the entire transcriptome in an unbiased manner has 
become easier in recent years due to the development of RNA-sequencing (RNA-Seq).  
RNA-Seq is a high throughput method of sequencing cDNA libraries and the general 
workflow is illustrated in Figure 1.   RNA input for library creation can either be 
selected for mature, polyadenylated RNA using oligo-dT magnetic beads, or total RNA 
can be used as input with rRNA removal beads to clear ribosomal RNA.  The next 
steps, cDNA synthesis and fragmentation can be interchanged depending on the aim of 
the study. Fragmenting the RNA before cDNA synthesis gives a more uniform 
sequence coverage over the gene body but fewer reads at the ends of transcripts25, 
while fragmenting after shows a strong 3’ bias26. Strand specific information can also 
be obtained if uracil is incorporated during the 2nd strand synthesis portion of the cDNA 
protocol and then later degraded using uracil-DNA glycosylase.  It is also possible, 
however, to skip cDNA synthesis entirely and sequence the RNA directly such as in the 
method described by Ozsolak et al.27, but this method was not utilized in the thesis 
work described herein.  Adapters are then ligated so that each fragment has the same 3’ 
and 5’ sequence for PCR amplification. Libraries are attached to a flowcell containing a 
dense lawn of primers.  For downstream signal detection, amplification of each cDNA 
fragment is needed. Colonies of each sequence are generated by bridge PCR.  
Sequencing with illumina technology uses fluorescently labeled dNTPs with a 
reversible terminator so only a single nucleotide can be added each cycle. Once the 
microscope captures the fluorescent signal the terminator is cleaved so the next base 
can be added.  This process can be repeated up to 150 times with little error and then 
the process can be repeated using the opposite ended primer (paired end) for a potential 
300 base pairs of sequence information.  Each sequenced fragment is then stitched back 
together using a reference genome where overall counts per gene can be used for gene 
expression analysis.     
 
RNA-Seq has advantages over microarray in gene expression quantification, as it does 
not rely on probe design and, as such, both known and novel genes can be interrogated.  
RNA-Seq has much greater dynamic range than microarrays 28,29,  spanning over five 
orders of magnitude25.  Correlation between protein and gene quantification is stronger 
when using RNA-Seq over microarray30,31, suggesting more accurate capture of 
biological information.   Information pertaining to splicing can also be extracted using 
coverage per exon and reads that span more than one exon, which are also known as 
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junction reads32.  As RNA-Seq contains sequence-specific information, sequence 
mismatches between RNA and DNA, such as those resulting from RNA editing, can 
also be identified33.  With the proper depth of coverage34, RNA-Seq is capable of 
giving us a robust and complex view of the transcriptome. 
 
Collectively, these different methodological approaches have been used to generate a 
view of the complement of mRNA that includes data at the level of whole gene, exon 
and single base pair level. Regulation of mRNA expression at each of these levels 
includes distinct biological mechanisms and is therefore worth discussing separately. 
 
1.3 REGULATION OF THE TRANSCRIPTOME 
1.3.1 Gene expression 
Regulating the overall amount of RNA molecules produced from a given gene can be 
accomplished in multiple ways.  First, RNA polymerase must be able to bind the DNA 
in order for the DNA to be transcribed.  If a section of DNA is tightly bound to 
histones, RNA polymerase cannot gain access and no gene product can be made.  
Modifications to histone proteins35 and DNA methylation36 dictate the strength of their 
interaction and therefore how accessible any particular gene is for transcription.  If the 
nucleoprotein complex containing histones and DNA is in an open conformation, 
transcription factors can bind and either recruit or impede RNA polymerase37.   
Subsequently, transcribed RNA is converted into mature RNA via post-transcriptional 
modifications each having a potential impact on overall mRNA quantity, which will be 
discussed further below.  
 
Modulation of gene expression is critical to many biological processes including 
morphogenesis and cell differentiation. In multi-tissue gene expression studies using 
microarrays, only 1-7.5% of the genes measured were ubiquitously expressed, 
suggesting that gene regulation contributes to the transcriptome complexity needed to 
derive different cell and tissue types38–40 . In these studies, only a small fraction of 
genes were utilized in any single tissue type, indicating that gene expression is not 
regulated as a simple on/off mechanism. Ramskold et al. used RNA-Seq to measure 
gene expression in multiple tissues and found that approximately 75% of all genes are 
ubiquitously expressed41. In the same study, it was found that of all the tissues 
sequenced, brain was one of the most complex.  With such a large number of genes 
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sharing expression across tissue types, mechanisms such as splicing and editing may 
also play a role in tissue specificity. 
 
1.3.2 Splicing 
 
 
 
Figure 2. This figure was adapted from Licatalosi et al.  demonstrates the different 
types of alternative splicing that can occur as indicated by the dotted lines42. 
Exons are in green, introns in grey, the 5’UTR is in blue and the 3’UTR is in pink. 
 
Splicing, the removal of non-coding intronic sequences and the joining of exons, is 
required in order to form mature RNA.  This process occurs in the nucleus by the 
spliceosome, a large complex of proteins and small nuclear ribonucleic particles 
(snRNPs)43,44.   Introns contain a specific 5’ donor site, a 3’ acceptor site, and a branch 
site near the 3’ end for recognition and removal by the spliceosome. Non-splicsosomal 
proteins can enhance or repress the use of splice sites by binding to exonic sequences, 
allowing for these exons to be included or excluded. This mechanism of alternative 
splicing leads to the creation of multiple isoforms from the same gene and thus 
proteomic diversity (Figure 2). Studies utilizing exon junction microarrays have found 
that as many as 74% of multi-exon genes have alternative splicing events45–47 and 
RNA-Seq estimates that an even higher proportion of genes may be spliced 48,49.   
Splicing plays an important role in neurodevelopment, synaptic plasticity and 
strength50, and the mammalian brain has been found to have the one of the highest 
number of alternative transcripts compared to other tissue types48,51. For instance, 
Exon 
skipping 
Mutually 
exclusive exons 
        
      
       
Alternate UTR 
      Intron retention 
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isoforms of the drosophila homologue of dscam mediate axon guidance52, while 
neurexin splice variants in the rat brain have critical roles in synaptogenesis53.    
 
There are also cases in which intronic sequences are retained.  This form of alternative 
splicing is thought to be less common than other forms of alternate splicing but there 
have been relatively few studies investigating intron retention on a transcriptome wide 
level to ascertain their true frequency.  In two RNA-Seq studies, the human brain was 
shown to have higher levels of intron retention compared to liver54,55.   Intron retention 
may play a vital role in the brain, for example by generating calcium channel 
diversity56.  Intron retention in KCNMA1 RNA promotes the inclusion of a stress axis-
regulated exon (STREX) and reduction of either the intron or the STREX exon reduced 
burst firing in hippocampal neurons56.  
 
Alternative splicing can also influence the regulation of transcript expression by 
changing mRNA stability, affecting the efficiency of translation, altering the number of 
miRNA sites or switching localization signals42,57.   Many regulatory elements that are 
involved in these processes are found in the untranslated regions (UTRs) of genes.  For 
instance, the subcellular localization of WT1, a tumor suppressor gene, depends on the 
alternative splicing of a gene region including its zinc finger58. Isoforms of the divalent 
metal transporter known as nramp2 can either include or exclude an iron response 
element found in its 3’UTR59, where is it then expressed primarily in the duodenum60 
or in erythroid cell precursors respectively61.  Interestingly, the 3’UTR regions in the 
mammalian brain are much longer than in other tissues41,62. 
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1.3.3 A-to-I RNA editing 
 
 
 
Figure 3.  This figure was adapted from Hogg et al. and demonstrates ADAR 
binding to double stranded RNA from both intronic and exonic sequences and 
then the deamination that occurs63.   
 
An additional source of transcriptome diversity is generated at the single base level via 
RNA editing illustrated in Figure 3.  Adenosine to inosine substitutions in mammalian 
RNA are the most widely understood RNA editing events and are carried out by 
adenosine deaminases (ADARs), of which there are three isoforms; ADAR, ADAR2, 
and ADAR3.  ADAR1 and ADAR2 are ubiquitously expressed, with expression levels 
are highest in the brain64,65 while ADAR3 is exclusively expressed in the brain66,67.  
ADARs act on double stranded RNA specific and may require dimerization to be 
enzymatically active68,69, although ADAR3 does not seem dimerize68 and is also 
enzymatically inactive to known substrates and synthetic dsRNA67.  Though other 
double stranded binding proteins have been found to have structural rather than 
sequence specificity70, Lehmann et al. found ADAR1 and ADAR2 share a 5’ sequence 
preference while only ADAR2 has a 3’ preference71.  ADARs are localized primarily in 
the nucleolus and are bound to ribosomal RNA72 but can translocate to the nucleus 
 
 
Intron Exon 
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upon expression of ADAR substrates such as Gria273.  
 
Inosine is recognized as guanosine in translation and as such editing in the coding 
region of a gene can result in a change in the amino acid sequence74. Editing may be 
particularly important in the brain as there are multiple isoforms of neurotransmitter 
receptors that are targeted by ADARs75.  In mice, editing of Gria2 leads to the 
impermeability of this glutamate channel to calcium ions.  If only the unedited isoform 
is present mice die approximately two weeks after birth due to seizures76.  Looking 
across mouse strains the majority of A-to-I editing sites are highly conserved77 
supporting the idea that editing is biologically important.   Editing is also found in non-
mammalian species, in octopuses RNA editing plays a role in the temperature 
adaptability of potassium channels78, again showing that RNA editing may influence 
neuronal excitability.   
 
RNA editing in the noncoding region of a gene can result in altered splicing, nuclear 
retention, or stability of the transcript79–82.  For example, ADAR2 may to regulate its 
own expression via the creation of an alternate splice site by auto-editing80. 
Hyperedited RNAs are bound and anchored to the nuclear matrix via the p54nrb 
complex to prevent them from being exported from the nucleus79.  Several studies have 
reported that viral RNA undergoes a high level of editing83,84 and it possible that 
nuclear retention of these promiscuously edited RNAs is therefore an anti-viral 
mechanism85. 
 
1.4 GENETIC VARIABILITY 
Variation in the genome can play role in controlling gene expression, thereby adding 
another layer of complexity to the transcriptome.  Single nucleotide polymorphisms 
(SNPs) a common form of variation in mammalian genomes.  With the development of 
high throughput SNP arrays, capturing this variation on a genome-wide scale is 
relatively straightforward and cost-effective. Associations between genetic variants and 
gene expression, where gene expression is treated as a quantitative trait, identify 
expression quantitative trait loci (eQTLs).  The majority of eQTLs are found in cis 
rather than in trans.  The strongest signals between correlated SNPs and gene 
expression are within 1 Mb on either side of the transcriptional start site (TSS) of the 
gene of origin86–88.  SNPs in such regions may affect the strength of a transcription 
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factor binding to the promoter site, thereby modulating the amount of mRNA 
transcribed.  
 
Many previous studies examining eQTLs have used microarrays to estimate gene 
expression86–89 potentially missing additional transcriptomic events such as splicing. A 
study by Kwan et al. using exon arrays found that out of all transcript-SNP pairs, 55% 
were isoform changes but only 39% were whole gene expression level changes90, 
which stresses the importance of measuring the expression level of each transcript.  
RNA-Seq may therefore be suitable for assessing transcriptomic genetic associations.  
Pickrell et al. using RNA-Seq in lymphoblastoid cell lines and reported measurable 
associations between genetic variation and splicing91.    
 
One might typically expect equal expression of each allele of a heterozygous haplotype, 
but this is not always the case.  For example, X-inactivation is the random silencing of 
one of the two copies of the X chromosome in each cell in females, thereby balancing 
the amount of expression to be equivalent to males.  However, about 15% of X-linked 
genes in human and 3% in mice escape this inactivation92.  Another form of 
monoallelic gene expression is genomic imprinting where autosomal genes are 
expressed in a parent-of-origin fashion, via inherited epigenetic marks such as DNA 
methylation and histone modification93.  Additionally, expression of some genes is 
subject to allelic imbalance, where in a heterozygous haplotype one allele is expressed 
more than the other.  RNA-Seq may be able to find such allele-specific expression 
information in a transcriptome wide manner.  In the same study mentioned, Pickrell et 
al. could also quantify the amount each allele was expressed.  Of the 222 putative cis-
eQTLS with quantifiable exonic SNPs 88% were driven by more reads from the higher 
expressing haplotype91.   
 
Genetic variation can be a risk factor for disease94.  SNP chip data along with 
phenotypic information can be used to investigate associations between genetic 
variation and disease as in genome-wide association studies (GWAS).  GWAS can be 
used to find SNPs that mark chromosomal regions and disease but they don’t indicate 
any biological relevance for that association.  By definition variants found in GWAS 
are present in the control population, so it is possible to overlay these with eQTLs.  Any 
SNPs that are associated with risk of disease and that are also in eQTL would suggest 
that expression levels of that specific gene are associated with disease. Supporting this 
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idea, previous studies show that GWAS hits paired with eQTL data can improve the 
ability to find true associations95,96.  However, these associations are more likely to be 
found when the gene is expressed in the tissue type observed97.  
 
1.5 CELLULARITY 
The brain is a complex tissue with a heterogeneous cellular composition. For example, 
the cerebral cortex is organized into six layers each having differing densities and 
distributions of neuronal cell populations98.  These neurons also project to other regions 
in the brain depending on their function.  For instance in the primary visual cortex, 
layer 4 is thicker than other layers as it receives a large number of projections from the 
thalamus99,100, whereas in the primary motor cortex the thickest layer is 5 as it contains 
a large number of neurons projecting to the spinal cord101.  Another type of 
organization found in subcortical structures are tight clusters of neurons in nuclei, an 
example being the substantia nigra which contains a large number of dopaminergic 
projection neurons. With all of this heterogeneity, homogenization of brain tissue may 
complicate measures of gene expression if certain cell types age more quickly or are 
more affected by disease. 
 
Cell specificity is of particular importance in neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s disease.    In many of these diseases there is evidence of 
preferential neuronal vulnerability, such as the prominent but not exclusive loss of 
dopaminergic neurons of the substantia nigra pars compacta in Parkinson’s disease.  
Being able to separate out specific cell types for gene expression quantification may 
therefore be useful in understanding the molecular basis of neurodegenerative diseases.  
Laser capture microdissection (LCM) is one technique that can be utilized to isolate 
subpopulations of cells with the caveat that any method used for identification of the 
cells of interest cannot degrade the RNA needed for downstream analysis.  If the cell 
type has a relatively unique morphology, such is the case for Purkinje cells, cresyl 
violet staining alone may suffice for identification and capture.  In these types of 
experiments population each neuron must be individually captured and the amount of 
RNA acquired is small.  For example, approximately 300 dopaminergic cells contain 
around 10-20 ng of RNA102.  With two rounds of amplification microarray analysis is 
possible but RNA-Seq has required substantially more RNA input.  Picelli et al. created 
a method called Smart-seq2 for creating cDNA libraries from single captured cells with 
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pictogram amounts of RNA103, and Deng et al. used this method with single cells from 
mouse embryos demonstrating that minimal amounts of laser captured cells can be used 
for robust RNA-Seq analysis104.  In their study analyzing gene expression in hundreds 
of singular mouse cells they found a number of genes show expression for only one 
allele in a completely stochastic manner illustrating the heterogeneity in individual 
cells.  
 
1.6 THE DEVELOPING BRAIN 
The cellular and molecular complexity of the mature adult brain discussed is influenced 
by processes in development and by the formation of neuronal circuits that are 
experience dependent105,106.  Brain development requires the coordinated expression of 
many genes in a spatially and temporally appropriate context107,108.  A number of 
studies have employed microarray technology in an attempt to study the molecular 
changes occurring during brain development on a genome wide scale109–112.      
 
There are many examples of regulated alternative splicing in neuronal 
development50,113.  In mice, fetal Mapt has only minor incorporation of exon 10 but by 
postnatal day 24 all tau contains this exon114.  The glutamate receptor gene Gria2 has a 
pair of mutually exclusive exons leading to two splice isoforms, flip and flop115, and in 
rats the isoform containing the flip exon is expressed at stable levels throughout 
development while the isoform incorporating flop is low until postnatal day 8116.  In 
general, retention of introns is also high in the brain and is developmentally regulated 
as levels of retention are higher in the fetal brain as compared to the adult54. One 
example of intron retention during development is in the role Robo3 plays in axon 
guidance117.  The Robo3 isoform captaining an intronic sequence (Robo3.2) is 
expressed but translationally repressed allowing for attraction to the spinal cord 
midline. Once the axon crosses the spinal cord midline, it receives signals from the 
floor plate to translate Robo3.2 allowing nonsense-mediated decay to occur, causing 
repellence away from midline. The brain also has been found to have longer 3’UTR 
regions than 41,62 and this lengthening of UTRs occurs during development118. 
 
A-to-I editing also seems to be important in development. ADAR2 knock out mice 
demonstrate perinatal lethality, dying of seizures a few weeks after birth76, while 
knocking out ADAR1 is embryonic lethal, although this seems to be due to lack of 
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erythropoiesis in the liver119.  Looking at 28 specific editing sites across development in 
the mouse brain Wahlstedt et al.  found that the majority showed a relatively low 
editing efficiency that increased over time33. 
 
1.7 AGING IN THE BRAIN 
One of the strongest risk factors for neurodegenerative diseases is age120,121.   Aging of 
the brain is a complex set of events that include both aspects under genetic control and 
stochastic events122.  While the molecular mechanisms underlying aging are poorly 
understood, several studies have shown correlations in gene expression levels and aging 
in the human brain123–126.  However, comparing these datasets reveals that only a few 
age-related expression changes have been consistently found.  Kang et al. observed that 
while abundant and drastic expression changes were seen during prenatal development, 
the changes in adult aging were fewer and tended to be more modest127. To date, no 
reports using RNA-Seq to study aging in the brain have been published and so it 
remains possible that there are additional associations with aging that are yet to be 
identified. 
 
Singular examples of aberrant splicing have been shown to play a role in 
neurodegenerative diseases.  For example, an unbalanced ratio of splice isoforms of 
MAPT has been found in FTLD (frontotemporal lobar degeneration)128,129.   There is 
some evidence that changes in splicing occur during normal aging.  For example in, 
Harries et al. have reported that deregulation of mRNA processing occurs with aging in 
human blood130.  In a study done in human brain, splicing changes associated with 
normal aging were also found in FTLD and AD (Alzheimer’s Disease) cases 
irrespective of age131, illustrating how aging may predispose the brain to certain 
neurodegenerative diseases.   
 
Finally there are potential links between RNA editing and aging.  ADAR2 and ADAR3 
are reported to contain SNPs that are associated with extreme old age in the New 
England Centenarian study, and these findings were replicated in three independent 
centenarian datasets132.   Knocking out either of the ADAR orthologues decreased 
lifespan in the model organism Caenorhabditis elegans.  ADAR2 knockout mice die 
shortly after birth, but if these mice also carry a mutation for the edited base in Gria2 
they have normal life spans76 indicating that ADAR2 may have a stronger role in 
development versus aging.  Focusing on ADAR output, Holmes et al. quantified the 
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amount of editing per site in a selected number of sites in rat but did not find any 
differences associated with aging62.  However, a study in human brain found an age 
related decrease in editing of Cyfip2 but not in Gabra3134.  The differences between 
studies may be explained by the fact that mice and rats lack a long enough life span to 
reach these age related transcriptomic changes, or that an association between aging 
and ADAR activity may be unique to humans.  One possible way to interrogate 
associations of editing with aging in an unbiased manner would be to use RNA-Seq on 
a human brain cohort with a suitably large age range.  
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2 AIMS 
The goal of my thesis project is to gain a better understanding of the complexity of 
the brain transcriptome at several different levels, using both human brain 
samples and model organisms. I initially focused on the interplay between genetic 
variation and gene expression in the human brain, generating a data set that can 
be used to elucidate potential associations between normal genetic variation and 
disease.  As well as genetic variants, a major risk factor for neurological diseases is 
aging.  I therefore also focused on normal aging in human post mortem brain to 
find age related gene expression changes that may prime the brain for 
neurodegenerative conditions.    
 
A major aim of my thesis work was to shift the gene expression quantification 
technique from microarray to RNA-Seq.  As there are many well-documented 
transcriptomic changes during development, I generated a preliminary dataset of 
embryonic versus adult mouse cerebral cortex.  The discovery that RNA-Seq could 
be used to find and quantify RNA-editing sites lead to further characterization of 
A-to-I editing in a knock out mouse model. Finally, I then applied the RNA-Seq 
methods to human brain samples with a view to revisiting the relationship 
between age and gene expression.     
 
Aim 1: Quantify mRNA abundance in human brain and blood samples using 
microarrays and query the relationship between GWAS risk variants and eQTLs. 
Aim 2: Quantify mRNA abundance in human brains and laser-captured Purkinje 
cells across age ranges using microarray to find potential associations between 
gene expression and aging.   
Aim 3: Quantify expression, splicing, and editing in E17 and adult mouse cerebral 
cortex using RNA-Seq to discover differential transcriptomic events.   
Aim 4: Quantify expression, splicing, and editing in Adar2-/- Gria2R/R and Adar2+/+ 
Gria2R/R littermate controls using RNA-Seq to find ADAR2 specific substrates and 
examine the potential role of ADAR2 in gene expression and splicing regulation.   
Aim 5: Quantify expression, splicing, and editing in the human brain series using 
RNA-Seq to find associations between transcriptomic changes and aging. 
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3 MATERIALS AND METHODS 
3.1 RNA EXTRACTION 
I extracted total RNA from fresh frozen brain using a tissue homogenizer and trizol 
(papers I-V).  Peripheral blood was collected using PAXgene tubes and RNA was 
extracted using the PAXgene Blood mRNA kit according to the manufactures protocols 
(paper I).  For Purkinje cell isolation (paper II) tissue was immersed in Shandon M-1 
embedding matrix and stored at −80°C until use. Cryostat sections (7–8 μm thick) were 
cut and stained with Cresyl Violet. Laser-capture microdissection was performed with 
ArcturusXT microdissection system. Between 70 and 150 excised Purkinje cells were 
selected from the slide surface and captured on LCM Macro Caps. Cellular RNA was 
recovered from the collected cells using PicoPureTM RNA isolation kit and treated 
with RNase-free DNase. RNA quality was measured using either the 260 to 280 ratio 
using a nanodrop (paper I) or the Agilent 2100 Bioanalyzer RNA Nano Chip (papers II-
V).    
 
3.2 MICROARRAY 
Samples were biotinylated and amplified using the Illumina® TotalPrep-96 RNA 
Amplification Kit (papers I-II). Two rounds of amplification was necessary for Purkinje 
cell RNA and was carried out with the Ambion MessageAmp II aRNA kit (paper II). 
Amplified RNA was hybridized onto HumanHT-12_v3 Expression BeadChips 
(Illumina). These arrays contain 48,804 probes estimating expression of ~25,000 
annotated genes from the RefSeq (Build 36.2, release 22) and Unigene (Build 199).  
Raw intensity values for each probe were normalized using cubic spline in BeadStudio 
(Illumina) then log2 transformed. Individual probes were included in analysis if they 
were detected (P < 0.01) in more than 95% of samples in the series.  
 
3.3 QRT-PCR 
We synthesized cDNA from Trizol-extracted RNA using the SuperScript III First-
Strand Synthesis System.  We measured cDNA abundance using Sybr Green on an 
Applied BioSystems HT-7900 qRT-PCR system. We performed serial dilutions of 
cDNA to find primer pairs with 100% efficiency and a single product on the 
disassociation curve. We used Ppid and Ubc (paper III) or β-actin (paper II) as 
normalization genes. In paper III regression was used to compare estimates of fold 
  17 
differences found in RNA-Seq as compared to qRT-PCR.  In paper II relative 
expression levels were then plotted against age after correction for other known 
covariates. 
3.4 GENOTYPING 
In paper I genomic DNA was extracted using phenol–chloroform and genotyping was 
performed using the Illumina Infinium HumanHap550 v3, Human610-Quad v1 or 
Human660W-Quad v1 Infinium Beadchip and common SNPs across all platforms were 
identified for each sample. SNPs were excluded if they showed < 95% genotyping 
success rate per SNP, minor allele frequency (MAF) < 0.01 or Hardy–Weinberg 
equilibrium (HWE) p-value < 1 x 10-7.  Markov Chain based haplotyper was used to 
impute non-assayed genotypes for blood and brain datasets independently using the 
June 2010 release of the 1000 Genomes Project build-36 reference panel, using default 
settings for MACH. Imputed SNPs were excluded from the analysis if their minor 
allele frequency (MAF) was < 0.01 and if their r2 was < 0.3.  Trait and disease 
associated SNPs were extracted from the NHGRI catalog of published GWAS at 
http://www.genome.gov/gwastudies/ on July 30th 2011. Analyses were restricted to the 
following criteria: discovery p-value < 1 x 10-8, initial sample size > 1000 (or 1000 
cases in binomial analyses), replication sample size > 500 (or 500 cases in binomial 
analyses), number of SNPs > 100,000, samples of European ancestry and risk allele 
frequency of SNP(s) greater or equal to 0.01.  
 
3.5 EXPRESSION QUANTITATIVE TRAIT LOCI 
In each brain region, mRNA probes within 500 kb of the chromosomal location of 
each SNP were incorporated into linear regression modeling using 
MACH2QTLv1.08 in paper I. Estimates of the association between the allelic dose of 
each SNP as a predictor of proximal gene expression levels were generated. These 
linear regression models were adjusted for both biological and methodological 
covariates which are known to affect expression profiles135. SNPs with fewer than 3 
minor homozygotes detected (based on either genotyped SNPs or maximum 
likelihood genotypes from imputation) were excluded from analyses. A consensus set 
of results was extracted from the frontal cortex, cerebellum and blood eQTL datasets 
with identical overlapping combinations of GWAS SNPs and proximal cis mRNA 
probes. 
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Significant associations were determined within each tissue type using a 5% FDR 
adjustment for multiple testing. Proportions of tested associations were calculated per 
tissue based on this subset of the eQTL results, and were compared using chi-squared 
tests. 
 
3.6 CALCULATING ASSOCAITIONS BEWTEEN AGING AND 
EXPRESSION 
In paper II we used genotype data to perform a principal components analysis for 
identity by state of genotype and took the first two principal components, PC1 and 
PC2, from this analysis to estimate overall genetic distance within the sample series. 
Cubic spline normalization was applied to raw output from array scans, then expression 
values were corrected for known covariates of gender, post-mortem interval (PMI), 
principal components PC1 and PC2 from genotyping and hybridization batch using 
multivariate regression the same as in eQTL analysis above except that age was not 
specified in the model.  The residuals for expression after covariate correction were 
then tested against age using linear regression. P-values were adjusted for multiple 
testing using a false discovery rate (FDR) correction set at 0.05. Probes were included 
if detected in >95% of samples in each series for frontal cortex and cerebellum, while 
in the Purkinje cells dataset only probes that had shown prior evidence of association in 
the above datasets were tested. 
 
3.7 WGCNA ANALYSIS 
In paper II the R-based package WGCNA (Weighted gene correlation network 
analysis) was used for a weighted network level analysis136. Twenty-seven consensus 
modules for genes with similar expression patterns were identified using the discovery 
and replication dataset in the frontal cortex and cerebellum as well as the Purkinje cell 
dataset. Covariates were tested for correlation with each probe and then tested for 
module membership.  Enrichment for Gene Ontology (GO) terms within modules was 
performed using DAVID137,138. 
 
3.8 RNA SEQUENCING  
We used either purified poly(A)+ RNA (papers III, V) or total RNA (paper IV) for 
cDNA library synthesis.  mRNA libraries were created using the mRNA-Seq prep kit 
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with oligo(dT) priming as per the manufacturer’s protocol (papers III, V).  Total RNA 
was processed using ribo-Zero gold rRNA removal beads and then libraries were 
synthesized using the Tru-Seq stranded total RNA sample preparation kit as per the 
manufacturer’s protocol (paper IV). In paper III we hybridized a single library to each 
lane of a flow cell and 80-bp single end sequences were generated using an Illumina 
GA-II sequencer.  In paper IV samples were multiplexed and six libraries were 
hybridized to a lane with 100-bp paired end sequences being generated using the Hi-
Seq.  In paper V a single library was hybridized to each lane with 100-bp paired end 
sequences being generated using the Hi-Seq 2000. 
3.9 ANAYLSIS OF GENE EXPRESSION IN RNA-SEQ DATA 
Fastq files were aligned to the mouse reference genome (mm9) using Tophat and 
Bowtie (paper III and IV) applying the ensembl gtf option with the 
Mus_musculus.NCBIM37.61 gtf (a gene transfer format file) to build bowtie indexes 
(paper IV).  For paper V fastq files were aligned to the human reference genome (hg19) 
using Tophat and Bowtie applying the ensembl gtf option with the GRCh37.59 gtf to 
build bowtie indexes.  Reads were annotated and quantified to a given gene using the 
Python module HT-SEQ.  For gene counts the same ensembl gtf mentioned above was 
used to provide reference boundaries. We used either the R/Bioconductor package 
DESeq (paper III) or DESeq2 (paper V) for library size normalize and to perform a 
variance-stabilizing transformation139. Poisson distributions of normalized counts for 
each transcript were then compared across samples either using a negative binomial test 
(paper III and IV) or a generalized linear model (paper V). Multiple testing was 
corrected for using the Benjamini-Hochberg procedure. 
 
3.10 STATISTICAL ANALYSIS OF ALTERNATIVE EXON UTILIZATION 
In paper III an in house gtf was built with exon start and stop locations to quantify reads 
that fell within exon boundaries, and junction reads were analyzed separately with the 
start position and end position being treated as independent measures. We then used the 
ratio of gene count to exon count as input for DE-SEQ, specifically using gene/exon 
rather than exon/gene because the latter would be fractions and not suitable for DE-
SEQ, which requires integers. In paper IV the NCBIM37.61 gtf was flattened with the 
python script found in HT-SEQ to create the appropriate counting bins needed for 
downstream exon analysis.  We then used R/Bioconductor package DEXSeq140 for 
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library size normalize, variance-stabilizing transformation, and differential usage. 
3.11 EDITING ANALYSIS 
For papers III and IV BAMS (binary sequence alignment map format files) were first 
filtered for only singly mapped reads.   Variants were then called for each sample using 
SAMtools pileup with mm9 as a reference.  We created a merged table to include only 
variants shared by all samples within a given group. We extracted variants within a 
gene boundary and with A-to-I changes. Finally, we submitted sequences containing 
the candidate edit sites to UCSC BLAT to distinguish reads with single mismatches to 
the genomic sequence due to RNA editing from those due to inappropriate mapping to 
another part of the genome. We accepted candidate edits if the best scored alignment of 
the read included the site of the edited base from the original alignment; if there were 
multiple genomic alignments of equal or higher score, then the candidate edit site was 
discarded. For paper V variants for each of the 43 conserved sites found by Pino et 
al.141 were called as a listed input for each sample using SAMtools pileup with hg19 as 
a reference.  We calculated percentages using the total number of called bases at each 
site and dividing them by the number of edited sites.   
 
3.12 RNA EDITING VALIDATION BY RT-PCR AND SEQUENCING  
In paper III cDNA was made from RNA extracted with trizol using the Supercript III 
First-Strand Synthesis System from Invitrogen.   We designed primer pairs that were 
approximately 150 base pairs away from the editing site and spanned an exon junction 
to avoid genomic DNA amplification. We also designed a genomic DNA primer to 
span the same site that amplified a product of similar size when used with one of the 
cDNA primers.  Amplification of cDNA and genomic DNA was then performed with 
Fast Start Master Mix.  Products were separated on a 1.5% agarose gel, cut out and 
extracted DNA using a QIAquick gel extraction kit. We cloned DNA into the PCR8-
TA cloning vector (Invitrogen) in One Shot Mach1-T1 Chemically competent cells and 
sequenced 24 colonies from three biological replicates for each edit site and 12 colonies 
from genomic DNA using a 3730 capillary sequencer.  
 
  21 
4 RESULTS AND DISCUSSION 
4.1 PAPER I 
Genome-wide association studies (GWAS) have played a useful role in finding many 
single nucleotide polymorphisms (SNPs) associated with common traits, including 
diseases.  These studies generally do not, however, demonstrate direct biological 
relevance of disease associated SNPs. Expression quantitative trait loci (eQTL) studies 
look at the association between SNPs and gene expression levels. Therefore, in paper I 
we extracted all known SNPs associated with human traits based on GWAS and used 
these SNPs for eQTL discovery. eQTLs discovered in this manner would suggesting 
altered gene expression levels may underlie the  GWAS association. Choosing the 
tissue type that is relevant to the disease or phenotype observed is an important 
consideration when measuring gene expression levels in eQTL experiments.  While it 
may be easier to procure a blood sample than brain, one must consider that there are 
likely to be unique expression patterns in each tissue type not shared with the other.  
We therefore compared eQTLs in both blood142 and brain86 to gain a better 
understanding of how informative blood can be for brain related phenotypes.  Like 
previous eQTL studies involving more than one tissue or cell type, we found a small set 
of shared eQTLs across both tissues. eQTLs that were shared across tissues tended to 
have a larger effect sizes than tissue specific eQTLs143–147.  Looking at tissue specific 
eQTLs there was a subset in which the gene was not expressed in measurable levels in 
other tissues.  An example of this is the blood specific eQTL found for LRAP/ERAP2 
and rs2549794 a SNP associated with Crohn’s disease148, which was not expressed in 
brain at detectable levels.  However, when restricting the analysis to genes expressed in 
both tissue there were still examples of genes with similar expression levels but where 
there was a difference in how the genetic variants associated with transcript levels 
(Figure 4).  This study underlines the importance of tissue type in expression studies, 
and demonstrates GWAS data paired with eQTL data can yield biologically 
informative results. 
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Understanding the interplay between genetic variation and gene expression in the 
human brain can be used to help elucidate associations between normal genetic 
variation and disease.  We conclude that eQTL data from an appropriate tissue can be 
compared to GWAS nominated SNPs, giving a potential explanation of expression 
level changes as the cause of disease associations. 
 
4.2 PAPER II 
In paper II, we measured gene expression from bulk extracted frontal cortex and 
cerebellum from human brains across a wide age range, a replication dataset, and in 
isolated Purkinje cells collected via LCM.  We found that several associations between 
age and gene expression carried over from the discovery dataset to the replication 
dataset, with the caveat that the replication set had a smaller sample size.  Interestingly, 
more genes with age-associated changes were found in frontal cortex versus 
cerebellum.  This was consistent with data published by Fraser et al.149,  and may 
support the theory that differing brain regions age at differing rates.  In the laser 
captured Purkinje microarray expression dataset we noted increases in cell specific 
makers such as PCP2150 indicating effectiveness of the technique.  Looking only at 
significant expression age associations from the frontal cortex or cerebellum to 
interrogate potential correlations in LCM there were five genes with the greatest 
support for significance including some that were not significant in bulk cerebellum 
(Figure 5).  Comparing these hits to another brain dataset from Colantunoni et al. we 
found four out of these five to be significant illustrating the robustness of our 
findings151.   This work is of particular importance as it demonstrates that LCM 
samples can be used as input to measure gene expression using microarray 
technologies. 
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Figure 5. This figure illustrates the replicated age associated, with each plot 
showing associations between age and residual expression.  Frontal cortex is on 
the left hand panels, cerebellum is the central panels while Purkinje cells are on 
the right. 
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4.3 PAPER III 
Although measurements of gene expression have been performed using microarrays, 
this approach generally considers each 'gene' as a single unit. However, many tissues 
including the brain, in particular, show a large number of splicing and editing events. 
With this depth of complexity in mind, we chose to use newly developed RNA-Seq 
techniques to capture and quantify transcriptomic events in a global and unbiased 
manner. RNA-Seq is, however, still in its nascent stages with little consensus on how to 
handle data processing and quantification.   We therefore generated a preliminary 
dataset in paper III using RNA sequencing on samples from the cerebral cortex of 
embryonic day 17 and adult mouse brains.  We decided to use mouse as it is a 
commonly used laboratory model organism, and there is a wealth of published 
information on differential expression, splicing, and RNA editing in pre- and post-natal 
tissue.  These published differences were therefore used to estimate the accuracy of the 
results found by deep sequencing methods. Our analysis revealed that there are 
numerous differences in RNA expression, splicing, and editing between embryonic and 
adult tissue.  There were over 4,000 genes that were differentially expressed (Figure 6).  
 
Figure 6. Differential expression, with log2 fold differences in normalized 
expression in adult and embryonic cerebral cortex plotted on the x-axis and the –
log10 adjusted p-value on the y-axis.  Genes are colored based on the log10 base 
mean expression 
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Gene ontology analysis illustrated that genes more highly expressed in the adult brain 
had more enrichment in neurotransmission or ion homeostasis while the majority of 
genes with higher expression in the embryonic brain were involved with cell division, a 
finding that is recapitulated in other studies109–111,152.  We found 387 exons that were 
differentially expressed with a fairly equal division of significance between adult and 
embryonic brains (Figure 7).   
 
 
Figure 7. This is the alternative exon utilization with proportion of inclusion of 
each event in the adult on the x-axis and the proportion of embryonic on the y-
axis.  
 
In our analysis of A-to-I editing we discovered 176 sites with a majority of these 
residing in the 3’UTR repeat regions of genes (Figure 8), a finding that has been 
reported in previous studies153–156.   
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Figure 8. The is the average percentage edited for each A-to-I site in the adult  
cortex on the y-axis and the embryonic cortex on the x-axis. 
 
Interestingly there is an increase in editing sites, mostly in the coding region, over 
development.  These results were biologically robust as they validated in a second 
animal cohort, and accurate as they were confirmed with more traditional quantification 
methods.  Our RNA-Seq dataset has also been made publically available for additional 
data mining. 
 
4.4 PAPER IV 
We performed RNA-Seq on the frontal cortices of ADAR2-/- GRIA2R/R mice and their 
ADAR2+/+ GRIA2R/R littermates, quantifying overall gene expression splicing and most 
importantly editing transcriptome wide.  We found 71 editing sites that had at least 
partial ADAR2 specificity with a majority of these being in the coding region of genes 
(figure 9) 
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.    
Figure 9.  A-to-I editing percentages with control on the x-axis and ADAR2-/- 
GRIA2R/R on the y-axis. 
 
It has been found in previous studies that ADAR2 shows a base preference immediately 
before and after the edit site71, but aligning all differential edits in our dataset did not 
yield any sequence specificity.   Interestingly, besides ADAR2 expression, there was 
only a single statistically significant differentially expressed gene, Flnb.  Also, despite 
the finding that ADAR2 may associate with spliceosomal proteins157, there were only 
three exons that showed statistically significant usage with none of these signals 
reaching two fold.  This work illustrates the importance of ADAR2 in site-specific 
changes of protein coding sequences but also suggests that ADAR2 does not have a 
major role in splicing or gene expression in vivo. 
 
4.5 PAPER V 
Previously we have used microarray technologies to show correlations in gene 
expression levels and aging in the human brain in an attempt to better understand the 
molecular mechanisms of aging. In paper II we only found five age-related expression 
changes that were consistently significant in multiple datasets. To further explore the 
association between aging and gene expression we decided to employ RNA-Seq on 60 
neurologically normal human brains of varying ages.  We found a large number of 
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genes that are associated with aging including several that had not previously been 
identified by microarrays.  These gene expression changes also had consistent 
biological relevance as those that decreased with age were more involved in synaptic 
transmission while those that increased had more involvement in immune response 
(examples in Figure 10).  
   
 
Figure 10.  This is a plot illustrating examples of age associated gene expression 
changes.  On the left panel is GRIK1, a gene involved in synaptic transmission, 
while the right panel is CFH, a gene involved in the immune response. 
 
Although we only found sex chromosomal genes were differential expressed when 
comparing male versus female frontal cortices, a study using exon arrays found splicing 
differences in autosomal genes in frontal cortex when comparing across gender158.  
This finding illustrates the need for an in depth splicing analysis of out dataset for both 
potential gender and age differences.  Finally we found a single editing site, in the gene 
cdh22, to be associated with aging. These results show that RNA-Seq can be used to 
identify novel associations between aging and gene expression, including editing 
changes.     
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5 CONCLUSIONS 
Paper I: 
 Tissue specific eQTLs were found 
 Some unique eQTLs were due to the gene only being expressed in that 
particular tissue 
 This study illustrates the importance of using the correct tissue in eQTL 
mapping 
 It also demonstrated that SNPs found in GWAS paired with expression can 
yield biologically informative results 
Paper II: 
 Many genes show some evidence of age-association in the human brain but 
they are often modest 
 Only a small subset of associations carried over from the discovery set to the 
replication set 
 More genes with age-associated gene changes were found in the frontal cortex 
as compared to the cerebellum supporting the theory that brain regions age at 
different rates 
 Comparing LCM to both datasets there were five genes with the greatest 
support for significance 
Paper III: 
 There was a large set of statistically significant differentially expressed genes  
 Differential exon usage was found in both adult and embryonic  
 Both novel and previously cited editing sites were found and quantified 
 Some edit sites increased with age, most commonly those found within the 
coding region of genes 
Paper IV: 
 Adar2-/-/Gria2R/R mice have decreases in multiple editing sites with the majority 
being found in the coding regions of genes as compared to their littermate 
controls 
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 Adar2-/-/Gria2R/R mice do not have major differences in total gene expression or 
splicing as compared to their littermate controls, arguing against ADAR2 
playing an important regulatory role in these pathways. 
Paper V: 
 Batch, PMI, and RIN have an affect on gene expression as measured by RNA-
Seq 
 Only genes found on sex chromosomes were differentially expressed when 
comparing male versus female samples but the strength of these genes were 
large 
 A large number of genes had a more modest association with age 
 Those genes with a decrease in expression across age had a gene ontology 
enrichment in synaptic transmission.  Genes that were more expressed with age 
showed the strongest association with GO categories in immune response 
 
  32 
 
  33 
6 ACKNOWLEDGEMENTS 
 
Mark Cookson 
Thank you for taking me on as a summer student all those years ago, I bet you didn’t 
know what you signed up for back then!   I appreciate all the time you spent giving me 
advice on how to present and write in the scientific world.  You have helped mould me 
into what I hope is a great scientist.     
 
Dagmar Galter 
Thank you for all your positivity and kind words. You have been wonderful helping to 
guide me through the Swedish process, thank you for being so tolerant of my many 
mistakes.   
 
The Olson Group 
Thank you for your support and for welcoming me into your lab.  I enjoyed sharing all 
the Swedish traditions and science with you. 
 
The Cookson Group 
Thank you for the scientific and emotional support throughout the years, and thanks for 
all the moves you helped me make throughout DC and to Sweden and back again! 
 
Lars Olson 
I have been amazed at your breadth and depth of knowledge and your ability to 
embrace new things. 
 
Brian Traynor 
Thanks for letting me be a part of the ALS world through participating in bench work 
with your group and for taking me to meetings. 
 
Andy Singleton 
Thank you for putting up with my random questions and for with our cubicles noise 
levels! 
 
My Family 
Thank you for all the love and support.  Thanks mom and dad for dealing with an 
exceptionally precocious child! 
 
 
 
    
 
 
  34 
7 REFERENCES 
1. Crick, F. Central dogma of molecular biology. Nature 227, 561–563 (1970). 
2. Thomas, P. S. Hybridization of denatured RNA transferred or dotted 
nitrocellulose paper. Methods Enzymol. 100, 255–266 (1983). 
3. Khandjian, E. W. & Méric, C. A procedure for Northern blot analysis of native 
RNA. Anal. Biochem. 159, 227–232 (1986). 
4. Siebert, P. D. Quantitative rt-PCR. Methods Mol. Med. 26, 61–85 (1999). 
5. Udvardi, M. K., Czechowski, T. & Scheible, W.-R. Eleven golden rules of 
quantitative RT-PCR. Plant Cell 20, 1736–1737 (2008). 
6. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR 
data by geometric averaging of multiple internal control genes. Genome Biol. 3, 
RESEARCH0034 (2002). 
7. Joyce, C. Quantitative RT-PCR. A review of current methodologies. Methods 
Mol. Biol. Clifton NJ 193, 83–92 (2002). 
8. Freeman, W. M., Walker, S. J. & Vrana, K. E. Quantitative RT-PCR: pitfalls and 
potential. BioTechniques 26, 112–122, 124–125 (1999). 
9. Hoefler, H. et al. In situ hybridization methods for the detection of somatostatin 
mRNA in tissue sections using antisense RNA probes. Histochem. J. 18, 597–604 
(1986). 
10. Lewis, M. E., Krause, R. G., 2nd & Roberts-Lewis, J. M. Recent developments in 
the use of synthetic oligonucleotides for in situ hybridization histochemistry. 
Synap. N. Y. N 2, 308–316 (1988). 
11. Kwon, S. Single-molecule fluorescence in situ hybridization: quantitative imaging 
of single RNA molecules. BMB Rep. 46, 65–72 (2013). 
12. Schena, M., Shalon, D., Davis, R. W. & Brown, P. O. Quantitative monitoring of 
gene expression patterns with a complementary DNA microarray. Science 270, 
467–470 (1995). 
13. McLachlan, G. J., Do & Ambroise, C. Analyzing microarray gene expression 
data. (Wiley-Interscience, 2004). at 
<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=
nlabk&AN=128122> 
14. Epstein, C. B. & Butow, R. A. Microarray technology - enhanced versatility, 
persistent challenge. Curr. Opin. Biotechnol. 11, 36–41 (2000). 
15. Harbig, J., Sprinkle, R. & Enkemann, S. A. A sequence-based identification of the 
genes detected by probesets on the Affymetrix U133 plus 2.0 array. Nucleic Acids 
Res. 33, e31 (2005). 
16. Mecham, B. H. et al. Increased measurement accuracy for sequence-verified 
microarray probes. Physiol. Genomics 18, 308–315 (2004). 
17. Sharov, V. et al. The limits of log-ratios. BMC Biotechnol. 4, 3 (2004). 
18. Nadon, R. & Shoemaker, J. Statistical issues with microarrays: processing and 
analysis. Trends Genet. TIG 18, 265–271 (2002). 
19. Okoniewski, M. J. & Miller, C. J. Hybridization interactions between probesets in 
short oligo microarrays lead to spurious correlations. BMC Bioinformatics 7, 276 
(2006). 
20. Binder, H. & Preibisch, S. Specific and nonspecific hybridization of 
oligonucleotide probes on microarrays. Biophys. J. 89, 337–352 (2005). 
21. Etienne, W., Meyer, M. H., Peppers, J. & Meyer, R. A., Jr. Comparison of mRNA 
gene expression by RT-PCR and DNA microarray. BioTechniques 36, 618–620, 
622, 624–626 (2004). 
  35 
22. Morey, J. S., Ryan, J. C. & Van Dolah, F. M. Microarray validation: factors 
influencing correlation between oligonucleotide microarrays and real-time PCR. 
Biol. Proced. Online 8, 175–193 (2006). 
23. Van der Brug, M., Nalls, M. A. & Cookson, M. R. Deep sequencing of coding 
and non-coding RNA in the CNS. Brain Res. 1338, 146–154 (2010). 
24. Mardis, E. R. Next-generation DNA sequencing methods. Annu. Rev. Genomics 
Hum. Genet. 9, 387–402 (2008). 
25. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping 
and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621–
628 (2008). 
26. Nagalakshmi, U. et al. The transcriptional landscape of the yeast genome defined 
by RNA sequencing. Science 320, 1344–1349 (2008). 
27. Ozsolak, F. et al. Direct RNA sequencing. Nature 461, 814–818 (2009). 
28. ’t Hoen, P. A. C. et al. Deep sequencing-based expression analysis shows major 
advances in robustness, resolution and inter-lab portability over five microarray 
platforms. Nucleic Acids Res. 36, e141 (2008). 
29. Cloonan, N. et al. Stem cell transcriptome profiling via massive-scale mRNA 
sequencing. Nat. Methods 5, 613–619 (2008). 
30. Fu, X. et al. Estimating accuracy of RNA-Seq and microarrays with proteomics. 
BMC Genomics 10, 161 (2009). 
31. Ning, K., Fermin, D. & Nesvizhskii, A. I. Comparative analysis of different label-
free mass spectrometry based protein abundance estimates and their correlation 
with RNA-Seq gene expression data. J. Proteome Res. 11, 2261–2271 (2012). 
32. Bryant, D. W., Jr, Priest, H. D. & Mockler, T. C. Detection and quantification of 
alternative splicing variants using RNA-seq. Methods Mol. Biol. Clifton NJ 883, 
97–110 (2012). 
33. Wahlstedt, H., Daniel, C., Ensterö, M. & Ohman, M. Large-scale mRNA 
sequencing determines global regulation of RNA editing during brain 
development. Genome Res. 19, 978–986 (2009). 
34. Sims, D., Sudbery, I., Ilott, N. E., Heger, A. & Ponting, C. P. Sequencing depth 
and coverage: key considerations in genomic analyses. Nat. Rev. Genet. 15, 121–
132 (2014). 
35. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 
(2007). 
36. Keshet, I., Lieman-Hurwitz, J. & Cedar, H. DNA methylation affects the 
formation of active chromatin. Cell 44, 535–543 (1986). 
37. Lemon, B. & Tjian, R. Orchestrated response: a symphony of transcription factors 
for gene control. Genes Dev. 14, 2551–2569 (2000). 
38. Su, A. I. et al. Large-scale analysis of the human and mouse transcriptomes. Proc. 
Natl. Acad. Sci. U. S. A. 99, 4465–4470 (2002). 
39. Su, A. I. et al. A gene atlas of the mouse and human protein-encoding 
transcriptomes. Proc. Natl. Acad. Sci. U. S. A. 101, 6062–6067 (2004). 
40. Zhang, W. et al. The functional landscape of mouse gene expression. J. Biol. 3, 21 
(2004). 
41. Ramsköld, D., Wang, E. T., Burge, C. B. & Sandberg, R. An abundance of 
ubiquitously expressed genes revealed by tissue transcriptome sequence data. 
PLoS Comput. Biol. 5, e1000598 (2009). 
42. Licatalosi, D. D. & Darnell, R. B. RNA processing and its regulation: global 
insights into biological networks. Nat. Rev. Genet. 11, 75–87 (2010). 
43. Jurica, M. S. & Moore, M. J. Pre-mRNA splicing: awash in a sea of proteins. Mol. 
Cell 12, 5–14 (2003). 
  36 
44. Rino, J. & Carmo-Fonseca, M. The spliceosome: a self-organized macromolecular 
machine in the nucleus? Trends Cell Biol. 19, 375–384 (2009). 
45. Johnson, J. M. et al. Genome-wide survey of human alternative pre-mRNA 
splicing with exon junction microarrays. Science 302, 2141–2144 (2003). 
46. Pan, Q. et al. Revealing global regulatory features of mammalian alternative 
splicing using a quantitative microarray platform. Mol. Cell 16, 929–941 (2004). 
47. Le, K. et al. Detecting tissue-specific regulation of alternative splicing as a 
qualitative change in microarray data. Nucleic Acids Res. 32, e180 (2004). 
48. Pan, Q., Shai, O., Lee, L. J., Frey, B. J. & Blencowe, B. J. Deep surveying of 
alternative splicing complexity in the human transcriptome by high-throughput 
sequencing. Nat. Genet. 40, 1413–1415 (2008). 
49. Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. 
Nature 456, 470–476 (2008). 
50. Li, Q., Lee, J.-A. & Black, D. L. Neuronal regulation of alternative pre-mRNA 
splicing. Nat. Rev. Neurosci. 8, 819–831 (2007). 
51. Yeo, G., Holste, D., Kreiman, G. & Burge, C. B. Variation in alternative splicing 
across human tissues. Genome Biol. 5, R74 (2004). 
52. Wojtowicz, W. M., Flanagan, J. J., Millard, S. S., Zipursky, S. L. & Clemens, J. 
C. Alternative splicing of Drosophila Dscam generates axon guidance receptors 
that exhibit isoform-specific homophilic binding. Cell 118, 619–633 (2004). 
53. Ullrich, B., Ushkaryov, Y. A. & Südhof, T. C. Cartography of neurexins: more 
than 1000 isoforms generated by alternative splicing and expressed in distinct 
subsets of neurons. Neuron 14, 497–507 (1995). 
54. Ameur, A. et al. Total RNA sequencing reveals nascent transcription and 
widespread co-transcriptional splicing in the human brain. Nat. Struct. Mol. Biol. 
18, 1435–1440 (2011). 
55. Kapranov, P. et al. The majority of total nuclear-encoded non-ribosomal RNA in 
a human cell is ‘dark matter’ un-annotated RNA. BMC Biol. 8, 149 (2010). 
56. Bell, T. J. et al. Intron retention facilitates splice variant diversity in calcium-
activated big potassium channel populations. Proc. Natl. Acad. Sci. U. S. A. 107, 
21152–21157 (2010). 
57. Kalsotra, A. & Cooper, T. A. Functional consequences of developmentally 
regulated alternative splicing. Nat. Rev. Genet. 12, 715–729 (2011). 
58. Larsson, S. H. et al. Subnuclear localization of WT1 in splicing or transcription 
factor domains is regulated by alternative splicing. Cell 81, 391–401 (1995). 
59. Lee, P. L., Gelbart, T., West, C., Halloran, C. & Beutler, E. The human Nramp2 
gene: characterization of the gene structure, alternative splicing, promoter region 
and polymorphisms. Blood Cells. Mol. Dis. 24, 199–215 (1998). 
60. Canonne-Hergaux, F., Gruenheid, S., Ponka, P. & Gros, P. Cellular and 
subcellular localization of the Nramp2 iron transporter in the intestinal brush 
border and regulation by dietary iron. Blood 93, 4406–4417 (1999). 
61. Canonne-Hergaux, F., Zhang, A. S., Ponka, P. & Gros, P. Characterization of the 
iron transporter DMT1 (NRAMP2/DCT1) in red blood cells of normal and 
anemic mk/mk mice. Blood 98, 3823–3830 (2001). 
62. Miura, P., Shenker, S., Andreu-Agullo, C., Westholm, J. O. & Lai, E. C. 
Widespread and extensive lengthening of 3’ UTRs in the mammalian brain. 
Genome Res. 23, 812–825 (2013). 
63. Hogg, M., Paro, S., Keegan, L. P. & O’Connell, M. A. RNA editing by 
mammalian ADARs. Adv. Genet. 73, 87–120 (2011). 
64. Melcher, T. et al. A mammalian RNA editing enzyme. Nature 379, 460–464 
(1996). 
  37 
65. O’Connell, M. A. et al. Cloning of cDNAs encoding mammalian double-stranded 
RNA-specific adenosine deaminase. Mol. Cell. Biol. 15, 1389–1397 (1995). 
66. Chen, C. X. et al. A third member of the RNA-specific adenosine deaminase gene 
family, ADAR3, contains both single- and double-stranded RNA binding 
domains. RNA N. Y. N 6, 755–767 (2000). 
67. Melcher, T. et al. RED2, a brain-specific member of the RNA-specific adenosine 
deaminase family. J. Biol. Chem. 271, 31795–31798 (1996). 
68. Cho, D.-S. C. et al. Requirement of dimerization for RNA editing activity of 
adenosine deaminases acting on RNA. J. Biol. Chem. 278, 17093–17102 (2003). 
69. Gallo, A., Keegan, L. P., Ring, G. M. & O’Connell, M. A. An ADAR that edits 
transcripts encoding ion channel subunits functions as a dimer. EMBO J. 22, 
3421–3430 (2003). 
70. Ryter, J. M. & Schultz, S. C. Molecular basis of double-stranded RNA-protein 
interactions: structure of a dsRNA-binding domain complexed with dsRNA. 
EMBO J. 17, 7505–7513 (1998). 
71. Lehmann, K. A. & Bass, B. L. Double-stranded RNA adenosine deaminases 
ADAR1 and ADAR2 have overlapping specificities. Biochemistry (Mosc.) 39, 
12875–12884 (2000). 
72. Sansam, C. L., Wells, K. S. & Emeson, R. B. Modulation of RNA editing by 
functional nucleolar sequestration of ADAR2. Proc. Natl. Acad. Sci. U. S. A. 100, 
14018–14023 (2003). 
73. Desterro, J. M. P. et al. Dynamic association of RNA-editing enzymes with the 
nucleolus. J. Cell Sci. 116, 1805–1818 (2003). 
74. Sommer, B., Köhler, M., Sprengel, R. & Seeburg, P. H. RNA editing in brain 
controls a determinant of ion flow in glutamate-gated channels. Cell 67, 11–19 
(1991). 
75. Seeburg, P. H. RNA helicase participates in the editing game. Neuron 25, 261–
263 (2000). 
76. Higuchi, M. et al. Point mutation in an AMPA receptor gene rescues lethality in 
mice deficient in the RNA-editing enzyme ADAR2. Nature 406, 78–81 (2000). 
77. Danecek, P. et al. High levels of RNA-editing site conservation amongst 15 
laboratory mouse strains. Genome Biol. 13, 26 (2012). 
78. Garrett, S. & Rosenthal, J. J. C. RNA editing underlies temperature adaptation in 
K+ channels from polar octopuses. Science 335, 848–851 (2012). 
79. Zhang, Z. & Carmichael, G. G. The fate of dsRNA in the nucleus: a p54(nrb)-
containing complex mediates the nuclear retention of promiscuously A-to-I edited 
RNAs. Cell 106, 465–475 (2001). 
80. Rueter, S. M., Dawson, T. R. & Emeson, R. B. Regulation of alternative splicing 
by RNA editing. Nature 399, 75–80 (1999). 
81. Serra, M. J., Smolter, P. E. & Westhof, E. Pronounced instability of tandem IU 
base pairs in RNA. Nucleic Acids Res. 32, 1824–1828 (2004). 
82. Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. 
Annu. Rev. Biochem. 79, 321–349 (2010). 
83. Bass, B. L., Weintraub, H., Cattaneo, R. & Billeter, M. A. Biased hypermutation 
of viral RNA genomes could be due to unwinding/modification of double-
stranded RNA. Cell 56, 331 (1989). 
84. Hajjar, A. M. & Linial, M. L. Modification of retroviral RNA by double-stranded 
RNA adenosine deaminase. J. Virol. 69, 5878–5882 (1995). 
85. Kumar, M. & Carmichael, G. G. Nuclear antisense RNA induces extensive 
adenosine modifications and nuclear retention of target transcripts. Proc. Natl. 
Acad. Sci. U. S. A. 94, 3542–3547 (1997). 
  38 
86. Gibbs, J. R. et al. Abundant quantitative trait loci exist for DNA methylation and 
gene expression in human brain. PLoS Genet. 6, e1000952 (2010). 
87. Veyrieras, J.-B. et al. High-resolution mapping of expression-QTLs yields insight 
into human gene regulation. PLoS Genet. 4, e1000214 (2008). 
88. Myers, A. J. et al. A survey of genetic human cortical gene expression. Nat. 
Genet. 39, 1494–1499 (2007). 
89. Keane, T. M. et al. Mouse genomic variation and its effect on phenotypes and 
gene regulation. Nature 477, 289–294 (2011). 
90. Kwan, T. et al. Genome-wide analysis of transcript isoform variation in humans. 
Nat. Genet. 40, 225–231 (2008). 
91. Pickrell, J. K. et al. Understanding mechanisms underlying human gene 
expression variation with RNA sequencing. Nature 464, 768–772 (2010). 
92. Berletch, J. B., Yang, F., Xu, J., Carrel, L. & Disteche, C. M. Genes that escape 
from X inactivation. Hum. Genet. 130, 237–245 (2011). 
93. Reik, W. & Walter, J. Genomic imprinting: parental influence on the genome. 
Nat. Rev. Genet. 2, 21–32 (2001). 
94. Tsuji, S. Genetics of neurodegenerative diseases: insights from high-throughput 
resequencing. Hum. Mol. Genet. 19, R65–70 (2010). 
95. Emilsson, V. et al. Genetics of gene expression and its effect on disease. Nature 
452, 423–428 (2008). 
96. Nicolae, D. L. et al. Trait-associated SNPs are more likely to be eQTLs: 
annotation to enhance discovery from GWAS. PLoS Genet. 6, e1000888 (2010). 
97. Grundberg, E. et al. Population genomics in a disease targeted primary cell model. 
Genome Res. 19, 1942–1952 (2009). 
98. Economo, C. Cellular structure of the human cerebral cortex. (Karger, 2009). 
99. Hirsch, J. A. & Martinez, L. M. Laminar processing in the visual cortical column. 
Curr. Opin. Neurobiol. 16, 377–384 (2006). 
100. Montagnini, A. & Treves, A. The evolution of mammalian cortex, from 
lamination to arealization. Brain Res. Bull. 60, 387–393 (2003). 
101. Rivara, C.-B., Sherwood, C. C., Bouras, C. & Hof, P. R. Stereologic 
characterization and spatial distribution patterns of Betz cells in the human 
primary motor cortex. Anat. Rec. A. Discov. Mol. Cell. Evol. Biol. 270, 137–151 
(2003). 
102. Pietersen, C. Y., Lim, M. P., Macey, L., Woo, T.-U. W. & Sonntag, K. C. 
Neuronal type-specific gene expression profiling and laser-capture 
microdissection. Methods Mol. Biol. Clifton NJ 755, 327–343 (2011). 
103. Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat. 
Protoc. 9, 171–181 (2014). 
104. Deng, Q., Ramsköld, D., Reinius, B. & Sandberg, R. Single-cell RNA-seq reveals 
dynamic, random monoallelic gene expression in mammalian cells. Science 343, 
193–196 (2014). 
105. Innocenti, G. M. & Price, D. J. Exuberance in the development of cortical 
networks. Nat. Rev. Neurosci. 6, 955–965 (2005). 
106. Sur, M. & Rubenstein, J. L. R. Patterning and plasticity of the cerebral cortex. 
Science 310, 805–810 (2005). 
107. Miller, J. A. et al. Transcriptional landscape of the prenatal human brain. Nature 
508, 199–206 (2014). 
108. Liscovitch, N. & Chechik, G. Specialization of gene expression during mouse 
brain development. PLoS Comput. Biol. 9, e1003185 (2013). 
109. Mody, M. et al. Genome-wide gene expression profiles of the developing mouse 
hippocampus. Proc. Natl. Acad. Sci. U. S. A. 98, 8862–8867 (2001). 
  39 
110. Semeralul, M. O. et al. Microarray analysis of the developing cortex. J. 
Neurobiol. 66, 1646–1658 (2006). 
111. Matsuki, T., Hori, G. & Furuichi, T. Gene expression profiling during the 
embryonic development of mouse brain using an oligonucleotide-based 
microarray system. Brain Res. Mol. Brain Res. 136, 231–254 (2005). 
112. Díaz, E. et al. Molecular analysis of gene expression in the developing 
pontocerebellar projection system. Neuron 36, 417–434 (2002). 
113. Lee, C. J. & Irizarry, K. Alternative splicing in the nervous system: an emerging 
source of diversity and regulation. Biol. Psychiatry 54, 771–776 (2003). 
114. McMillan, P. et al. Tau isoform regulation is region- and cell-specific in mouse 
brain. J. Comp. Neurol. 511, 788–803 (2008). 
115. Sommer, B. et al. Flip and flop: a cell-specific functional switch in glutamate-
operated channels of the CNS. Science 249, 1580–1585 (1990). 
116. Monyer, H., Seeburg, P. H. & Wisden, W. Glutamate-operated channels: 
developmentally early and mature forms arise by alternative splicing. Neuron 6, 
799–810 (1991). 
117. Colak, D., Ji, S.-J., Porse, B. T. & Jaffrey, S. R. Regulation of axon guidance by 
compartmentalized nonsense-mediated mRNA decay. Cell 153, 1252–1265 
(2013). 
118. Ji, Z., Lee, J. Y., Pan, Z., Jiang, B. & Tian, B. Progressive lengthening of 3’ 
untranslated regions of mRNAs by alternative polyadenylation during mouse 
embryonic development. Proc. Natl. Acad. Sci. U. S. A. 106, 7028–7033 (2009). 
119. Wang, Q., Khillan, J., Gadue, P. & Nishikura, K. Requirement of the RNA editing 
deaminase ADAR1 gene for embryonic erythropoiesis. Science 290, 1765–1768 
(2000). 
120. Fjell, A. M. et al. What is normal in normal aging? Effects of aging, amyloid and 
Alzheimer’s disease on the cerebral cortex and the hippocampus. Prog. 
Neurobiol. (2014). doi:10.1016/j.pneurobio.2014.02.004 
121. Tan, C.-C. et al. Autophagy in aging and neurodegenerative diseases: implications 
for pathogenesis and therapy. Neurobiol. Aging 35, 941–957 (2014). 
122. Martin, G. M. The biology of aging: 1985-2010 and beyond. FASEB J. Off. Publ. 
Fed. Am. Soc. Exp. Biol. 25, 3756–3762 (2011). 
123. Lu, T. et al. Gene regulation and DNA damage in the ageing human brain. Nature 
429, 883–891 (2004). 
124. Berchtold, N. C. et al. Gene expression changes in the course of normal brain 
aging are sexually dimorphic. Proc. Natl. Acad. Sci. U. S. A. 105, 15605–15610 
(2008). 
125. Erraji-Benchekroun, L. et al. Molecular aging in human prefrontal cortex is 
selective and continuous throughout adult life. Biol. Psychiatry 57, 549–558 
(2005). 
126. Kumar, A. et al. Age-associated changes in gene expression in human brain and 
isolated neurons. Neurobiol. Aging 34, 1199–1209 (2013). 
127. Kang, H. J. et al. Spatio-temporal transcriptome of the human brain. Nature 478, 
483–489 (2011). 
128. Hong, M. et al. Mutation-specific functional impairments in distinct tau isoforms 
of hereditary FTDP-17. Science 282, 1914–1917 (1998). 
129. Jiang, Z., Cote, J., Kwon, J. M., Goate, A. M. & Wu, J. Y. Aberrant splicing of tau 
pre-mRNA caused by intronic mutations associated with the inherited dementia 
frontotemporal dementia with parkinsonism linked to chromosome 17. Mol. Cell. 
Biol. 20, 4036–4048 (2000). 
  40 
130. Harries, L. W. et al. Human aging is characterized by focused changes in gene 
expression and deregulation of alternative splicing. Aging Cell 10, 868–878 
(2011). 
131. Tollervey, J. R. et al. Analysis of alternative splicing associated with aging and 
neurodegeneration in the human brain. Genome Res. 21, 1572–1582 (2011). 
132. Sebastiani, P. et al. RNA editing genes associated with extreme old age in humans 
and with lifespan in C. elegans. PloS One 4, e8210 (2009). 
133. Holmes, A. P., Wood, S. H., Merry, B. J. & de Magalhães, J. P. A-to-I RNA 
editing does not change with age in the healthy male rat brain. Biogerontology 14, 
395–400 (2013). 
134. Nicholas, A. et al. Age-related gene-specific changes of A-to-I mRNA editing in 
the human brain. Mech. Ageing Dev. 131, 445–447 (2010). 
135. Trabzuni, D. et al. Quality control parameters on a large dataset of regionally 
dissected human control brains for whole genome expression studies. J. 
Neurochem. 119, 275–282 (2011). 
136. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation 
network analysis. BMC Bioinformatics 9, 559 (2008). 
137. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment 
tools: paths toward the comprehensive functional analysis of large gene lists. 
Nucleic Acids Res. 37, 1–13 (2009). 
138. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 
44–57 (2009). 
139. Anders, S. & Huber, W. Differential expression analysis for sequence count data. 
Genome Biol. 11, R106 (2010). 
140. Anders, S., Reyes, A. & Huber, W. Detecting differential usage of exons from 
RNA-seq data. Genome Res. 22, 2008–2017 (2012). 
141. Pinto, Y., Cohen, H. Y. & Levanon, E. Y. Mammalian conserved ADAR targets 
comprise only a small fragment of the human editosome. Genome Biol. 15, R5 
(2014). 
142. Wood, A. R. et al. Allelic heterogeneity and more detailed analyses of known loci 
explain additional phenotypic variation and reveal complex patterns of 
association. Hum. Mol. Genet. 20, 4082–4092 (2011). 
143. Dimas, A. S. et al. Common regulatory variation impacts gene expression in a cell 
type-dependent manner. Science 325, 1246–1250 (2009). 
144. Greenawalt, D. M. et al. A survey of the genetics of stomach, liver, and adipose 
gene expression from a morbidly obese cohort. Genome Res. 21, 1008–1016 
(2011). 
145. Nica, A. C. et al. The architecture of gene regulatory variation across multiple 
human tissues: the MuTHER study. PLoS Genet. 7, e1002003 (2011). 
146. Bullaughey, K., Chavarria, C. I., Coop, G. & Gilad, Y. Expression quantitative 
trait loci detected in cell lines are often present in primary tissues. Hum. Mol. 
Genet. 18, 4296–4303 (2009). 
147. Ding, J. et al. Gene expression in skin and lymphoblastoid cells: Refined 
statistical method reveals extensive overlap in cis-eQTL signals. Am. J. Hum. 
Genet. 87, 779–789 (2010). 
148. Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of 
confirmed Crohn’s disease susceptibility loci. Nat. Genet. 42, 1118–1125 (2010). 
149. Fraser, H. B., Khaitovich, P., Plotkin, J. B., Pääbo, S. & Eisen, M. B. Aging and 
gene expression in the primate brain. PLoS Biol. 3, e274 (2005). 
  41 
150. Oberdick, J., Levinthal, F. & Levinthal, C. A purkinje cell differentiation marker 
shows a partial dna sequence homology to the cellular sis/pdgf2 gene. Neuron 3, 
386 (1989). 
151. Colantuoni, C. et al. Temporal dynamics and genetic control of transcription in 
the human prefrontal cortex. Nature 478, 519–523 (2011). 
152. Kagami, Y. & Furuichi, T. Investigation of differentially expressed genes during 
the development of mouse cerebellum. Brain Res. Gene Expr. Patterns 1, 39–59 
(2001). 
153. Athanasiadis, A., Rich, A. & Maas, S. Widespread A-to-I RNA editing of Alu-
containing mRNAs in the human transcriptome. PLoS Biol. 2, e391 (2004). 
154. Neeman, Y., Levanon, E. Y., Jantsch, M. F. & Eisenberg, E. RNA editing level in 
the mouse is determined by the genomic repeat repertoire. RNA N. Y. N 12, 1802–
1809 (2006). 
155. DeCerbo, J. & Carmichael, G. G. SINEs point to abundant editing in the human 
genome. Genome Biol. 6, 216 (2005). 
156. Blow, M., Futreal, P. A., Wooster, R. & Stratton, M. R. A survey of RNA editing 
in human brain. Genome Res. 14, 2379–2387 (2004). 
157. Raitskin, O., Cho, D. S., Sperling, J., Nishikura, K. & Sperling, R. RNA editing 
activity is associated with splicing factors in lnRNP particles: The nuclear pre-
mRNA processing machinery. Proc. Natl. Acad. Sci. U. S. A. 98, 6571–6576 
(2001). 
158. Trabzuni, D. et al. Widespread sex differences in gene expression and splicing in 
the adult human brain. Nat. Commun. 4, 2771 (2013). 
 
